Candel Therapeutics, Inc. (CADL)

Market Cap	169.41M
Revenue (ttm)	n/a
Net Income (ttm)	-49.99M
Shares Out	32.08M
EPS (ttm)	-1.71
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	205,246
Open	5.41
Previous Close	5.41
Day's Range	5.13 - 5.43
52-Week Range	0.66 - 14.30
Beta	-0.94
Analysts	Strong Buy
Price Target	11.00 (+108.33%)
Earnings Date	Nov 11, 2024

About CADL

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 27, 2021
• Employees: 42
• Stock Exchange: NASDAQ
• Ticker Symbol: CADL
• Website: https://www.candeltx.com

Analyst Forecast

According to one analyst, the rating for CADL stock is "Strong Buy" and the 12-month stock price forecast is $11.0.

Price Target

$11.0

(108.33% upside)

Analyst Consensus: Strong Buy